Immunogenetic Profiling for Risk of Primary Graft Dysfunction after Heart Transplantation

心脏移植术后原发性移植物功能障碍的免疫遗传学分析 对于美国大约25万患有终末期心力衰竭的人来说， 移植（HT）仍然是金标准疗法。尽管长期生存率很高，但早期死亡率 由于感染、排斥和原发性移植物功能障碍（PGD），PGD，特别是， HT的毁灭性并发症，其中新同种异体移植物的急性失败导致血流动力学不稳定， 终末器官灌注不足因此，我们在此建议建立在有趣的初步数据基础上， CLEC4C的血浆水平，CLEC4C是一种作为浆细胞样树突状细胞的细胞表面受体的蛋白质 在移植前，在HT后随后发展PGD的患者中，pDC（pDC）的表达更高。具体来说，我们将 整合免疫分析、pDC和PBMC单细胞测序以及单细胞蛋白质组学， 分离的pDC以检验pDCS在HT中定量和功能富集的假设 接受者发展PGD。这项研究有可能确定临床相关的生物标志物在护理 可能有助于阐明PGD的潜在分子机制。

Immunogenetic Profiling for Risk of Primary Graft Dysfunction after Heart Transplantation For the approximately 250,000 people in the United States living with end-stage heart failure, heart transplantation (HT) remains the gold standard therapy. Despite excellent long-term survival, early mortality remains high as a result of infection, rejection, and primary graft dysfunction (PGD). PGD, in particular, is a devastating complication of HT in which acute failure of the new allograft leads to hemodynamic instability and end-organ hypoperfusion. Thus, we propose herein to build upon interesting preliminary data suggesting that plasma levels of CLEC4C, a protein that serves as a cell surface receptor for plasmacytoid dendritic cells (pDCs), are higher prior to transplant in patients who subsequently develop PGD after HT. Specifically, we will integrate immune profiling, single cell sequencing of pDCs and PBMCs, and single cell proteomics in isolated pDCs to test the hypothesis that pDCS are quantitatively and functionally enriched in HT recipient who develop PGD. This study has the potential to identify clinically relevant biomarkers in the care of HT recipients and may help to elucidate the underlying molecular mechanisms of PGD.